X

Company profile for Hibiskus BioPharma

Hibiskus BioPharma

HIBISKUS BIOPHARMA

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

No Content

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

Contact Supplier

Related Companies

Hibiskus aims to become the selective proteasome inhibitor company by targeting each of the 7 human proteasome catalytic ß subunits with its macrolactam drug candidates. While proteasome inhibition is an established mode of action for FDA-approved drugs, its applications to diseases have been relatively narrow, mostly multiple myeloma, a disorder of antibody-producing cells in the blood. The proteasome is present in all eukar...

Hibiskus aims to become the selective proteasome inhibitor company by targeting each of the 7 human proteasome catalytic ß subunits with its macrolactam drug candidates. While proteasome inhibition is an established mode of action for FDA-approved drugs, its applications to diseases have been relatively narrow, mostly multiple myeloma, a disorder of antibody-producing cells in the blood. The proteasome is present in all eukaryotic cells, so small molecules that selectively target one proteasome among many (and one sub-catalytic activity) have the potential for many pharmaceutical uses.